Octapharma USA starts phase 3 trial for hemophilia treatment
HOBOKEN, N.J. The U.S. subsidiary of a Swiss biotech company has started a late-stage trial of a new treatment for hemophilia that it calls the first of its kind.
Octapharma USA, owned by Lachen, Switzerland-based Octapharma AG, announced Monday the start of a phase 3 trial of a recombinant Factor VIII for the treatment of severe hemophilia A. The company said the treatment was the first rFVIII to be derived from a human cell line.
According to the National Institutes of Health, 90% of all hemophilia patients have hemophilia A, also known as Factor VIII deficiency.
Target launches anti-smoking campaign with American Cancer Society
MINNEAPOLIS — Target announced that it is launching a month-long anti-smoking campaign in connection with the American Cancer Society’s 2010 Great American Smokeout to support guests and team members in their efforts to quit smoking.
"Target is committed to helping our guests and team members reach their well-being goals, which may include quitting smoking, and we’re proud to work with the American Cancer Society for this year’s Great American Smokeout," said Dr. Joshua Riff, Target’s medical director. "As part of our focus on prevention, Target offers a variety of tools, tips and products for those who want to stop smoking and stay smoke-free. This campaign advances our prevention efforts and will ultimately lead to healthier communities."
The campaign will begin on Nov. 1 and will highlight Target’s assortment of stop-smoking aids and give greater visibility to Target Pharmacy and Target Clinic healthcare professionals, who can offer support, smoking-cessation materials and advice, the company reported. The campaign is anchored by in-store signing and informational brochures in all Target stores, as well as features in the weekly ad and at Target.com.
The American Cancer Society’s 35th annual Great American Smokeout takes place Nov. 18, and is designed to motivate and empower smokers with personalized tools, tips and support to help them quit for good.
GSK, Amicus to develop, commercialize Amigal
CRANBURY, N.J. British drug maker GlaxoSmithKline will work with U.S.-based Amicus Therapeutics to develop a drug for a rare genetic disease.
The two companies announced a deal to develop and commercialize Amigal (migalastat hydrochloride), a treatment for Fabry disease. Under the deal, GSK will pay Amicus $30 million upfront, as well as milestone payments of up to $170 million and royalties on future sales.
Fabry disease is a lysosomal storage disorder resulting from deficiencies of the enzyme alpha-galactosidase A. Lack of the enzyme results in buildup of a lipid called globotriaosylceramide, or GL-3, which is believed to cause the disease’s symptoms, such as pain, kidney failure and increased risk of heart attack and stroke. The disease affects 5,000 to 10,000 people worldwide.